CompletedPhase 2NCT00059904
Rituximab and Interleukin-2 in Treating Patients With Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma
Studying Plasmablastic lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Principal Investigator
- Tarun Kewalramani, MDMemorial Sloan Kettering Cancer Center
- Intervention
- aldesleukin(biological)
- Eligibility
- 18 years · All sexes
- Timeline
- 2003 – 2004
Study locations (1)
- Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00059904 on ClinicalTrials.govOther trials for Plasmablastic lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06781359Study on Plasmablastic Lymphoma PatientsFondazione Italiana Linfomi - ETS
- RECRUITINGPHASE2NCT04915248Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.Fondazione Italiana Linfomi - ETS
- RECRUITINGEARLY PHASE1NCT04139304A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic LymphomaAIDS Malignancy Consortium
- ACTIVE NOT RECRUITINGPHASE1NCT01961063Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin LymphomaCity of Hope Medical Center